Black patients suffer worse outcomes after percutaneous coronary intervention (PCI) than
White patients. Inequities in antiplatelet prescribing may contribute to this health disparity …

Beyond late-breaking clinical trials, the presentation of the European Society of Cardiology
(ESC) Guidelines has become a highly anticipated event at the annual ESC Congress. This …

Background: Antiplatelet therapy deescalation has been suggested as an alternative to
standard treatment with potent dual antiplatelet therapy (DAPT) for 1 year in low bleeding …

The role of antiplatelet therapy in patients with acute coronary syndromes is a moving target
with considerable novelty in the last few years. The pathophysiological basis of the treatment …

Introduction In patients with acute coronary syndromes (ACS) undergoing percutaneous
coronary intervention (PCI), dual antiplatelet therapy (DAPT) with a potent P2Y12 inhibitor is …

The intricate relationship between smoking and the effects of the antiplatelet drug
clopidogrel has been termed the “smoker's paradox”. This paradox details the enhanced …

Background Publication of the BRIGHT-4 trial results has restimulated discussion about the
optimal periprocedural antithrombotic strategy for patients undergoing percutaneous …

The objective of this study was to characterize clinician response following standardization
of pharmacogenetic (PGx) clinical decision support alerts at University of Florida (UF) …

Introduction Dual antiplatelet therapy (DAPT) represents the cornerstone of secondary
prevention in patients presenting with acute coronary syndrome (ACS) and undergoing …

Dual antiplatelet therapy—the combination of aspirin and a P2Y12 inhibitor—remains the
standard antiplatelet regimen recommended to prevent ischemic complications immediately …